Clinical Review of Malignant Melanoma Patients Treated at Shinshu University between 2000 and 2009

DOI
  • Nakamura Kenta
    Department of Dermatology, Shinshu University School of Medicine
  • Minagawa Akane
    Department of Dermatology, Shinshu University School of Medicine
  • Ashida Atsuko
    Department of Dermatology, Shinshu University School of Medicine
  • Koga Hiroshi
    Department of Dermatology, Shinshu University School of Medicine
  • Kiniwa Yukiko
    Department of Dermatology, Shinshu University School of Medicine
  • Okuyama Ryuhei
    Department of Dermatology, Shinshu University School of Medicine
  • Uhara Hisashi
    Department of Dermatology, Shinshu University School of Medicine

Bibliographic Information

Other Title
  • 信州大学における悪性黒色腫245例（2000～2009年）の臨床統計
  • シンシュウ ダイガク ニ オケル アクセイ コクショク シュ 245レイ(2000~2009ネン)ノ リンショウ トウケイ

Search this article

Abstract

The 245 patients with malignant melanomas treated at Shinshu University from 2000 to 2009 were reviewed. The patients with metastasis had been treated with conventional cytotoxic regimens and/or radiation but not with anti-CTLA-4 antibodies, anti-PD-1 antibodies or BRAF inhibitors. The disease-specific five-year survival rate was 100% among the stage 0 patients, 98% in stage I, 82% in stage II, 59% in stage III, and 18% in stage IV. Postoperative metastasis occurred in 51 patients. The median period until an initial metastasis was 13 months. The first metastasis occurred within 1 year in 49% of the patients, and at ≥5 years in 12% of the patients. The locations of initial metastases (the ratio of patients with metastasis in a particular organ to the total number of patients) were as follows: lung in 55%, skin and subcutis in 35%, lymph nodes in 24%, and brain in 12%. The methods that detected first metastasis were as follows: regular images (CT or PET) without any symptoms in 89% of lung metastasis and 64% of lymph node metastasis, and physical examination in 94% of skin and subcutaneous metastasis. These results suggest that the long-term follow-up with physical examinations and regular lung imaging are important for managing malignant melanoma patients. In addition, these data may be useful as a benchmark for comparing survival benefits afforded by novel therapies including immune-check-point inhibitors and molecular-target therapies, the use of which has begun in Japan.

Journal

Related Projects

See more

Keywords

Details

Report a problem

Back to top